BJMO - volume 12, issue 3, february 2018
J. Robijns PhD, S. Censabella , S. Claes , Luc Pannekoeke , Lore Bussé , D. Colson , Iris Kaminski , A. Maes MD, P. Bulens MD, M. Brosens , L. Noé MD, Ivo Lambrichts , A. Timmermans , V. Somers , J. Mebis MD, PhD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, PhD, S. Censabella , S. Engels , Guy Orye , S. Marquette MD, C. Van Narsenille , L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, PhD, S. Censabella , S. Engels , C. Van Narsenille , Guy Orye , S. Marquette MD, L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 11, issue 8, december 2017
J. Robijns PhD, S. Censabella , P. Bulens MD, A. Maes MD, L. Noé MD, M. Brosens , L. Van den Bergh MD, PhD, S. Claes , J. Mebis MD, PhD
Photobiomodulation therapy is based on the application of visible and/or (near-)infrared light on the target tissue. We performed a review of 34 articles on the use of photobiomodulation therapy in the management of cancer related lymphoedema, oral mucositis, radiodermatitis, chemotherapy-induced peripheral neuropathy, osteonecrosis of the jaw, and xerostomia/hyposalivation. The findings suggest that photobiomodulation therapy is a promising option for the management of these cancer therapy-related side effects.
(BELG J MED ONCOL 2017;11(8):364–374)
Read more
